Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nbf-006
- Development stage
- Phase 1
- Lead developer
- Nitto BioPharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NBF-006 is a proprietary small interfering RNA (siRNA)-based lipid nanoparticle drug designed to inhibit the expression of glutathione S-transferase pi (GSTP). GSTP is a phase II detoxification enzyme that also modulates key oncogenic pathways such as KRAS and JNK. By delivering GSTP siRNA directly to tumor cells, particularly in non-small cell lung cancer (NSCLC) with KRAS mutations, NBF-006 aims to disrupt MAPK and PI3K signaling pathways and induce apoptosis. Preclinical studies demonstrated significant antitumor activity and increased survival in animal models. In early-phase clinical trials, NBF-006 showed favorable safety and tolerability profiles with promising efficacy signals in heavily pretreated patients with NSCLC, colorectal cancer (CRC), and pancreatic cancer (PANC). The drug is being developed by Nitto Biopharma for intravenous administration.
- Other names
- NDT-05-1040NDT05-1040NDT 05-1040
02
Targets
GSTP1 (Glutathione S-transferase P)
Beyond the preview
Go deeper on nbf-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nbf-006.